Maya Martinez-Davis
Corporate Officer/Principal at GSK PLC
Profile
Maya Martinez-Davis is currently the President-US Pharmaceuticals at GSK Plc.
Prior to this, she was the Independent Director at Mirati Therapeutics, Inc. from 2018 to 2024 and the President-Biopharma Latin America at Merck KGaA from 2016 to 2019.
She completed her undergraduate degree at St. Louis University and her graduate degree at Instituto de Empresa SL.
Maya Martinez-Davis active positions
| Companies | Position | Start |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | 2019-12-31 |
Former positions of Maya Martinez-Davis
| Companies | Position | End |
|---|---|---|
| MIRATI THERAPEUTICS | Director/Board Member | 2024-01-22 |
| MERCK KGAA | Corporate Officer/Principal | 2019-07-31 |
Training of Maya Martinez-Davis
| St. Louis University | Undergraduate Degree |
| Instituto de Empresa SL | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| MERCK KGAA | Health Technology |
| GSK PLC | Health Technology |
| Private companies | 1 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Maya Martinez-Davis
